Matthew Fuller, PharmD

National PBM Clinical Pharmacy Program Manager, VHA Pharmacy Benefits Management Services, Hines, Illinois

PCC
Ultra–Low-Dose Mirtazapine for Chronic Insomnia
Original Research

March 10, 2026

Patients with insomnia disorder demonstrated a clinically relevant effect of low-dose mirtazapine (3.75 mg) on insomnia severity from 1–3 months
, , , et al

Consensus Report on XT Use in Practice

Read the full report
Figure: Graphic promoting Consensus Report on Xanomeline-Trospium; colorful net design shown with JCP logo in lower left.

Subscribe to read
more articles

Subscribe